Home › NDC Lookup › Ingredients › Olopatadine Hydrochloride › 46122-0671-27
👁️image loading
(from DailyMed)

OLOPATADINE HYDROCHLORIDE 2 mg/mL Solution, 1 bottle — NDC 46122-671-27 (Billing 46122-0671-27)

by Amerisource Bergen · 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC

This is a package of 1 bottle of OLOPATADINE HYDROCHLORIDE 2 mg/mL Solution from Amerisource Bergen, marketed since Jan 2021 and currently FDA-listed; retail pharmacies pay about $2.96 per mL (NADAC). It is this product's only package size.

NDC 46122-0671-27
🏷️ FDA NDC (as labeled) 46122-671-27 billing pads the product segment with a zero
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 46122-671-27
Product NDC 46122-671
11-digit billing NDC 46122067127
NCPDP billing unit ML — per mL (volume)
RxCUI 1111343
UNII 2XG66W44KF
Application # ANDA209995
SPL Set ID 067baa0b-5c01-4908-92de-ad79c73d2c37
Established class (EPC) Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer
Mechanism of action Histamine H1 Receptor Antagonists
Physiologic effect Decreased Histamine Release
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-01-19
Route OPHTHALMIC
Dosage form SOLUTION
Substance OLOPATADINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86802065102030
GPI class GNP Olopatadine HCl
GCN Seq No 062065
GCN 97848
HICL code 012815
Ingredient (HICL) Olopatadine Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6R
Therapeutic class — specific (HIC3) Eye Antihistamines
AHFS code 52:02.00.00
AHFS class Antiallergic Agents
FDB label name GNP OLOPATADINE 0.2% EYE DROP
FDB brand name Olopatadine Hcl
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 062065
  • GCN: 97848
  • GPI-14 (Medi-Span): 86802065102030
  • HICL (First Databank): 012815
  • AHFS class code: 52:02.00.00
  • RxCUI (RxNorm): 1111343
Why two NDCs? The FDA registers this code as 46122-671-27 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 46122-0671-27. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Histamine-1 Receptor Inhibitor class.

Pharmacologic class Histamine-1 Receptor Inhibitor, Histamine-1 Receptor Antagonist, Mast Cell Stabilizer
Drug family (ATC) Antiallergic agents, excl. corticosteroids, Other antiallergics
How it works Histamine H1 Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name GNP OLOPATADINE 0.2% EYE DROP Ingredient Olopatadine Hcl
📗 Our plain-language guide HelloPharmacist
  • The eye drops relieve itchy eyes from allergies, and some products relieve redness too. The nasal spray relieves seasonal allergic rhinitis symptoms in adults and children 6 and ol...
  • It depends on the product. Some eye drops are twice daily, 6 to 8 hours apart, and others once daily. The nasal spray is twice daily. Follow your label or prescriber.
  • Take your lenses out before using the drops and wait at least 10 minutes before putting them back. Don't wear lenses if your eyes are red. These drops aren't for contact lens irrit...
  • With the nasal spray, a bitter taste, headache, nosebleeds and sore throat are common. It can also make you drowsy, so be careful driving and skip alcohol.
📖 Read our full Olopatadine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Olopatadine Hydrochloride — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Olopatadine Hydrochloride (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $2.964 $7.41 / 2.5 ml
Medicaid paysCMS SDUD · 12 mo $6.43 $16.07 / 2.5 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $4.013 $2.822
▼ Down 26% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
46122-0671-27 You're viewing this Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC 2021-01-19 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Olopatadine Hydrochloride 2 mg/mL 24208-0617-01 Bausch 1 bottle $1.983 — Availability likely save 33%
Leader Olopatadine Hydrochloride 2 mg/mL 70000-0716-01 CARDINAL 1 bottle $1.983 — Availability likely save 33%
Olopatadine Hydrochloride 2 mg/mL 00536-1307-23 Rugby 1 bottle $2.964 — Availability likely —
olopatadine hydrochloride 2 mg/mL 16571-0861-25 Rising 2.5 ml $2.964 — Availability likely —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 43598-0764-02 Dr. 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mLthis 46122-0671-27 Amerisource 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 68001-0530-69 BluePoint 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 68001-0674-92 BluePoint 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 70069-0491-01 Somerset 1 bottle $2.964 — Availability likely —
Eye Allergy Itch Relief Once Daily Relief 2 mg/mL 70677-1155-01 Strategic 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 83324-0120-25 Chain 1 bottle $2.964 — Availability likely —
Eye Allergy Itch Relief 2 mg/mL 70000-0053-01 CARDINAL 1 bottle $3.096 — Availability likely +4%
Pataday Once Daily Relief 2 mg/mL 00065-8150-01 Alcon 1 bottle $5.893 — Availability likely +99%
Olopatadine Hydrochloride 2 mg/mL 00363-0869-01 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 00363-7131-25 Walgreens 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 00363-8022-39 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 11673-0688-25 Target 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 11822-0063-02 RITE 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 11822-9975-02 Rite 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 21130-0105-02 Albertsons 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 24208-0967-01 Bausch 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 30142-0026-27 Kroger 1 bottle — — FDA listed —
Once Daily Relief 2 mg/mL 37808-0045-25 H 1 bottle — — FDA listed —
Eye Allergy Itch Relief Once Daily Relief 2 mg/mL 43598-0827-02 Dr. 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 46122-0824-29 AmerisourceBergen 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 46708-0710-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 50090-5613-00 A-S 1 bottle — — FDA listed —
Allergy Relief Eye Drops 2 mg/mL 51316-0675-25 CVS 1 bottle — — FDA listed —
Retaine Allergy 5 mg/2.5mL 54799-0920-25 OCuSOFT 2.5 ml — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution Once Daily 2 mg/mL 55910-0137-25 DOLGENCORP, 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0007-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0010-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0013-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine hydrochloride 2 mg/mL 60505-6222-02 Apotex 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 62332-0502-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 62332-0710-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 63868-0821-25 Chain 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 63941-0024-39 Best 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic 2 mg/mL 68083-0231-01 Gland 1 bottle — — FDA listed —
Eye Allergy Itch Relief 2 mg/mL 69168-0495-77 Allegiant 2 bottles — — FDA listed —
CVS Eye Allergy Itch Relief Once Daily 2 mg/mL 69842-0269-25 CVS 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72036-0009-39 Harris 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72476-0851-21 Retail 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72657-0194-11 GLENMARK 2 bottles — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 73581-0709-02 YYBA 2 bottles — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 76162-0044-39 TOPCO 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 79481-1001-02 Meijer 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 79903-0001-39 Wal-Mart 1 bottle — — FDA listed —
Equate Olopatadine Hydrochloride 2 mg/mL 79903-0318-01 WAL-MART 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 80539-0001-39 Allwell 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 82442-0967-02 TARGET 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 73581-0712-02 YYBA 2 bottles — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 73581-0713-02 YYBA 2 bottles — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Jan 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII FZ989GH94E
    Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII GR686LBA74
    Sodium phosphate, dibasic is a salt derived from phosphoric acid. It acts as a buffer to help maintain the medicine's pH balance and may serve as a binder or filler in tablets and capsules.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesbenzalkonium chloride 0.01%, dibasic sodium phosphate, edetate disodium, hydrochloric acid/sodium hydroxide (adjust pH), povidone, sodium chloride and water for injection

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAmerisource Bergen
Application holderEUGIA PHARMA SPECIALITIES LTD
FDA applicationANDA209995 (ANDA)
Labeler code46122
First marketedJan 2021
Product typeHuman Otc Drug
Portfolio206 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 14 words ▾

Use temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander

⏱️ Dosage and Administration 56 words ▾

Directions adults and children 2 years of age and older: put 1 drop in the affected eye(s) once daily, no more than once per day if using other ophthalmic products while using this product, wait at least 5 minutes between each product replace cap after each use children under 2 years of age: consult a doctor

⚠️ Warnings 5 words ▾

Warnings For external use only

📦 Storage and Handling 16 words ▾

Other information only for use in the eye store between 2° to 25°C (36° to 77°F)

🧪 Active Ingredient 12 words ▾

Drug Facts Active ingredient Olopatadine (0.2%) (equivalent to olopatadine hydrochloride, USP 0.222%)

🧪 Inactive Ingredients 22 words ▾

Inactive ingredients benzalkonium chloride 0.01%, dibasic sodium phosphate, edetate disodium, hydrochloric acid/sodium hydroxide (adjust pH), povidone, sodium chloride and water for injection

🎯 Purpose 2 words ▾

Purpose Antihistamine

📄 Do Not Use 26 words ▾

Do not use if solution changes color or becomes cloudy if you are sensitive to any ingredient in this product to treat contact lens related irritation

📄 When Using This Product 43 words ▾

When using this product do not touch tip of container to any surface to avoid contamination remove contact lenses before use wait at least 10 minutes before reinserting contact lenses after use do not wear a contact lens if your eye is red

📄 Stop Use and Ask a Doctor If 28 words ▾

Stop use and ask a doctor if you experience: eye pain changes in vision increased redness of the eye itching worsens or lasts for more than 72 hours

📄 Keep Out of Reach of Children 20 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

📄 Questions or Comments 17 words ▾

Questions? ✆1-855-274-4122 Distributed By AmerisourceBergen 1 West First Avenue Conshohocken, PA 1942 Made in India Code: TS/DRUGS/13/2010

📄 Package Label / Principal Display Panel 107 words ▾

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-0.2% (2.5 mL Container) GOOD NEIGHBOR PHARMACY ® NDC 46122-671-27 Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% Antihistamine Eye Allergy Relief STERILE 2.5 mL (0.085 FL OZ) PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-0.2% (2.5 mL Container)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-0.2% (2.5 mL Container Carton) *Compare to the Active Ingredient in Pataday ® Once Daily Relief GOOD NEIGHBOR PHARMACY ® NDC 46122-671-27 NOW AVAILABLE without a prescription Olopatadine Hydrochloride Ophthalmic Solution, USP 0.2% Antihistamine Eye Allergy Relief Works in Minutes Relief from Allergens: • Pet Dander • Pollen ONCE • Grass • Ragweed DAILY STERILE 2.5 mL (0.085 FL OZ) PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-0.2% (2.5 mL Container Carton)

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
13.6K
Units reimbursed last 4 qtrs
39K
Gross reimbursed last 4 qtrs
$250.5K
Avg / prescription
$18.35
Avg / unit
$6.4299
Latest quarter Q1 2026
4.4KRx
Medicaid pays / mL
$6.4299
gross reimbursed
vs
NADAC / mL
$2.9636
acquisition cost
=
Spread
+$3.4663
+117% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
90% FFS
Fee-for-service · 12,244 Rx Managed care · 1,404 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 275 units · 4.8 per 100k residents MN Wisconsin: 233 units · 3.9 per 100k residents WI Michigan: 825 units · 8.2 per 100k residents MI New York: 23,284 units · 119 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 88 units · 1.3 per 100k residents IN Ohio: 345 units · 2.9 per 100k residents OH Pennsylvania: 1,083 units · 8.4 per 100k residents PA New Jersey: 350 units · 3.8 per 100k residents NJ Massachusetts: no data reported MA California: 9,890 units · 25.4 per 100k residents CA Utah: no data reported UT Colorado: 68 units · 1.2 per 100k residents CO Nebraska: 145 units · 7.3 per 100k residents NE Missouri: 780 units · 12.6 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 393 units · 4.5 per 100k residents VA Maryland: no data reported MD Connecticut: 50 units · 1.4 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: 80 units · 2.7 per 100k residents KS Arkansas: no data reported AR Tennessee: 265 units · 3.7 per 100k residents TN North Carolina: 330 units · 3.0 per 100k residents NC South Carolina: 268 units · 5.0 per 100k residents SC Delaware: 210 units · 20.4 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
1.2119
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 119 /100k
2 California 25.4 /100k
3 Delaware 20.4 /100k
4 Missouri 12.6 /100k
5 Pennsylvania 8.4 /100k
6 Michigan 8.2 /100k
7 Nebraska 7.3 /100k
8 South Carolina 5.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 46122-0669-78 · AmerisourceBergen 46122-0672-64 · Amerisource →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.